A place for precision medicine in bladder cancer: targeting the FGFRs by Di Martino, E et al.
This is a repository copy of A place for precision medicine in bladder cancer: targeting the 
FGFRs.




Di Martino, E, Tomlinson, DC orcid.org/0000-0003-4134-7484, Williams, SV et al. (1 more 
author) (2016) A place for precision medicine in bladder cancer: targeting the FGFRs. 
Future Oncology, 12 (19). pp. 2243-2263. ISSN 1479-6694 
https://doi.org/10.2217/fon-2016-0042
© 2016 Future Medicine Ltd. This is an author produced version of a paper published in 




Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright 
exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy 
solely for the purpose of non-commercial research or private study within the limits of fair dealing. The 
publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White 
Rose Research Online record for this item. Where records identify the publisher as the copyright holder, 
users can verify any specific terms of use on the publisher’s website. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 


































IgI IgII IgIII TK1 TK2















7 tumours + 3 cell lines (RT112, RT4, LUCC2)
IgI IgII IgIII
FGFR3
IgI IgI
1 760
TK2IgIII TK1
453
T1
